Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Adoption of all resolutions submitted to the vote of Shareholders Regulatory News: The Combined Shareholders’ Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY), chaired by Marc de Garidel, Chairman of the Board, was held today, in the presence of the members of the Board of D...
Regulatory News: In accordance with the provisions of Article L. 225-209 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and the General Regulation of the French Autorité des Ma...
Ipsen ( OTCPK:IPSEY ) inks a global licensing and joint development agreement with MD Anderson's Institute for Applied Cancer Sciences for an unnamed oncology drug candidate. More news on: Ipsen S.A. ADR, Healthcare stocks news, Stocks on the move, Read more ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group, and The University of Texas MD Anderson Cancer Center today announced a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by researchers in MD Anders...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that cabozantinib (Cabometyx ® ) and irinotecan liposome injection (Onivyde ® ) are the subject of 8 presentations at the 2018 American Society of Clinical Oncology (ASCO) annual meeting. The meeting takes place...
Regulatory News: Ipsen, (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group focused on innovation and specialty care today announced the launch of an employee share ownership plan. This plan aims to associate employees with the Group’s development and performance. Th...
Exelixis (NASDAQ: EXEL ) is up 5% premarket, albeit on only 100 shares, in response to its announcement that the European Commission has approved commercialization partner Ipsen's ( OTCPK:IPSEY )( OTCPK:IPSEF ) marketing application for CABOMETYX (cabozantinib) for the first-li...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has approved Cabometyx ® (cabozantinib) 20, 40, 60 mg for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma (aRCC). This approval...
Shares of emerging oncology star Exelixis ( EXEL ) have risen by an astounding 500% over the past three years. However, the stock finished slightly in the red over the past twelve months. While the stock is up 75% since I called it a ¨compelling buy¨ in late 2016, as a member of...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its sales for the first quarter of 2018. Q1 2018 Financial highlights: Group sales growth of 23.1%, driven by Specialty Care sales growth of 27.4%, refl...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...